Top Analyst Reports for Coca-Cola, Abbott & RTX

23.04.25 23:37 Uhr

Werte in diesem Artikel
Aktien

117,42 EUR 4,42 EUR 3,91%

64,79 EUR 0,37 EUR 0,57%

8,10 EUR 0,08 EUR 1,00%

Indizes

PKT PKT

39.606,6 PKT 419,6 PKT 1,07%

20.314,2 PKT 254,8 PKT 1,27%

16.708,1 PKT 407,6 PKT 2,50%

16.043,0 PKT 137,1 PKT 0,86%

1.257,6 PKT 43,7 PKT 3,60%

2.594,8 PKT 49,0 PKT 1,92%

5.375,9 PKT 88,1 PKT 1,67%

Wednesday, April 23, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Co. (KO), Abbott Laboratories (ABT) and RTX Corp. (RTX), as well as two micro-cap stocks Investors Title Co. (ITIC) and Armanino Foods of Distinction, Inc. (AMNF). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Back Up on Softening Stance from the White HouseToday's Featured Research ReportsCoca-Cola’s shares have outperformed the Zacks Beverages - Soft drinks industry over the past year (+23.1% vs. +5.6%). The company experiences positive business trends, as evidenced by its strong track record of beating expectations. In fourth-quarter 2024, the company exceeded sales and earnings estimates for the eighth consecutive quarter, with earnings showing year-over-year improvement.Results benefited from continued business momentum, aided by higher pricing across markets facing intense inflation and favorable mix. Coca-Cola's all-weather strategy, combining marketing, innovation and revenue growth management, supports its vision of a total beverage company and is expected to drive revenue growth in 2025.Coca-Cola has provided an optimistic view for 2025. However, Coca-Cola faces inflationary cost pressures due to higher commodity and material costs, as well as increased marketing investments.(You can read the full research report on Coca-Cola here >>>)Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+25.6% vs. +5.9%). The company’s pipeline is unlocking new growth opportunities, supporting the company’s positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business.Abbott is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. Within Nutrition, despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also adds to the worry.(You can read the full research report on Abbott here >>>)RTX’s shares have outperformed the Zacks Aerospace - Defense industry over the past year (+21.5% vs. +1.8%). The company ended the first quarter of 2025 on a solid note, with both its earnings and revenues having surpassed their respective Zacks Consensus Estimates.RTX continues to receive ample orders for its wide range of combat-proven defense products, which resulted in RTX registering a robust defense backlog of $92 billion as of March 31, 2025. Steadily improving commercial air traffic has also been boosting the company's sales. RTX’s shares have outperformed its industry in the past year.However, the uncertainties created by the recent imposition of U.S.-issued import tariffs and the counter-tariffs from other nations pose a risk for RTX. Supply-chain challenges continue to affect the aerospace sector, which may adversely affect RTX’s performance. The stock’s forward 12-month EV/SALES ratio is unimpressive when compared to its industry.(You can read the full research report on RTX here >>>)Shares of Investors Title have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+62.7% vs. +25.4%). This microcap company with market capitalization of $505.52 million remains committed to shareholder returns, maintaining a $0.46 quarterly dividend and issuing a $14.00 special dividend in December 2024, all funded through robust cash reserves.In 2024, title insurance premiums rose 19.3% to $204.3 million, with agency-sourced premiums up 27%, driven by favorable mortgage trends and geographic expansion. Operational improvements, including a 3.7% headcount reduction and lower personnel costs, boosted after-tax margins to 12%. Strategic IT investments support compliance and client trust in a digital-first environment.However, margin pressure is rising due to elevated commission payouts and a looming 10% rate cut in Texas. Regulatory costs are mounting across key states, and competition from larger national peers is intensifying. Off-balance sheet fiduciary risks, including $323.5 million in 1031 exchange deposits, further heighten operational exposure.(You can read the full research report on Investors Title here >>>)Armanino Foods of Distinction’s shares have outperformed the Zacks Food - Miscellaneous industry over the past year (+41% vs. -8.5%). This microcap company with market capitalization of $238.75 million delivered record profitability in 2024, driven by a gross margin expansion to 44% from 34.5%, reflecting improved operational efficiency, disciplined cost controls and strategic Capex.A strong balance sheet, with $28.22 million in cash, no debt and $26.2 million in working capital, supports its $12-million repurchase program and $1.5-million capex plan for 2025. Sales were $69.42 million (up 9% year over year), with diversified channel growth and expanding international reach.Consistent dividends, including 11 specials, highlight robust cash flow and earnings quality. Certified “AA” for food safety, Armanino Food’s high compliance standards support brand strength. Net income jumped 67% to $14.62 million, with the operating margin rising to 26.3%. Leadership continuity and insider alignment further reinforce long-term value creation.(You can read the full research report on Armanino Foods of Distinction here >>>)Other noteworthy reports we are featuring today include Netflix, Inc. (NFLX), Roche Holding AG (RHHBY) and Lowe's Companies, Inc. (LOW).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadCoca-Cola's (KO) Innovations & Pricing Efforts Bode WellMarket Expansion, EPD Business Growth Aid Abbott (ABT)Defense Orders Drive RTX Corporation (RTX), Despite Supply Chain WoesFeatured ReportsNetflix (NFLX) Rides on Subscriber Growth, Original ContentPer the Zacks analyst, Netflix's robust content portfolio is helping it gain ground globally. Increase in paid membership is driving the topline of the company.Vabysmo, Phesgo Fuel Roche (RHHBY), Pipeline Setbacks a WoePer the Zacks analyst, strong growth of Vabysmo, Phesgo, Ocrevus and Hemlibra boost Roche's top-line as legacy drugs face biosimilars. However, pipeline setbacks are a headwind.Lowe's (LOW) Omnichannel, Pro Customer Strategy to Lift SalesPer the Zacks analyst, Lowe's pro customer strategy and omni-channel efforts could drive sales growth. Online comparable sales rose 9.5% during the fourth quarter of fiscal 2024.Traction in Battery Management Solutions Aid Analog Devices (ADI)Per the Zacks analyst, Analog Devices is benefiting from a strong momentum in the electric vehicle space on the back of its robust Battery Management System solutions.Uniform Rental Unit to Aid Cintas (CTAS) amid Rising CostsPer the Zacks analyst, Cintas' Uniform Rental and Facility Services unit is driven by the penetration of additional products and services into existing customers. High costs remain a concern.Canadian Natural (CNQ) to Gain from 100% Ownership in AOSPThe Zacks analyst believes Canadian Natural's strategic acquisitions, including full AOSP ownership, will significantly improve its production capacity and cash flow prospects.W.R. Berkley (WRB) Solid Insurance Business Aid, Cat Loss AilPer the Zacks analyst, W.R. Berkley's Insurance business is set to grow on rate increases, and improving premiums from international unit. Yet, exposure to cat loss, increasing expenses drag margins.New UpgradesAffirm (AFRM) Rides On Active Merchant Numbers & GMV GrowthThe Zacks Analyst expects growth in Affirm's active merchant numbers and improvement in Gross Merchandise Value to fuel its top line. New deals and expansions will support performance boost.Jazz's (JAZZ) Oncology Drugs Fuel Sales & DiversificationWhile Jazz's sleep disorder portfolio has exhibited strong demand, the Zacks Analyst is impressed with the company's oncology drugs whose sales diversify the existing marketed portfolio.Loan Demand, Manageable Costs Support Hilltop Holdings (HTH)Per the Zacks analyst, decent loan demand, relatively higher rates and prudent expense management will aid Hilltop Holdings. A solid balance sheet makes its capital distributions sustainable.New DowngradesCompetition and Nil Dividend Payout Hurts Palantir (PLTR)Per the Zacks analyst, high competition demands tech and talent investment, raising Palantir's difficulty in balancing growth and profitability. A nil dividend payout deters income-seeking investors.High-Debt Burden & Stiff Rivalry Ail Western Digital (WDC)Per the Zacks analyst, stiff competition from other major storage players limits the growth prospects of Western Digital. Customer concentration and leveraged balance sheet are added woes.Delay in Rate Approval & Seasonality Ail FirstEnergy (FE)Per the Zacks analyst, FirstEnergy's financial condition could be negatively impacted by a delay in base rate request approval. Unfavorable weather conditions might also lower the top line.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report CocaCola Company (The) (KO): Free Stock Analysis Report Netflix, Inc. (NFLX): Free Stock Analysis Report Lowe's Companies, Inc. (LOW): Free Stock Analysis Report Investors Title Company (ITIC): Free Stock Analysis Report Armanino Foods of Distinction Inc. (AMNF): Get Free Report RTX Corporation (RTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Abbott Laboratories und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Abbott Laboratories

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Abbott Laboratories

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Coca-Cola Co.

Wer­bung

Analysen zu Coca-Cola Co.

DatumRatingAnalyst
22.04.2025Coca-Cola BuyUBS AG
22.04.2025Coca-Cola OverweightJP Morgan Chase & Co.
17.04.2025Coca-Cola BuyUBS AG
19.02.2025Coca-Cola OverweightJP Morgan Chase & Co.
12.02.2025Coca-Cola KaufenDZ BANK
DatumRatingAnalyst
22.04.2025Coca-Cola BuyUBS AG
22.04.2025Coca-Cola OverweightJP Morgan Chase & Co.
17.04.2025Coca-Cola BuyUBS AG
19.02.2025Coca-Cola OverweightJP Morgan Chase & Co.
12.02.2025Coca-Cola KaufenDZ BANK
DatumRatingAnalyst
24.07.2024Coca-Cola HaltenDZ BANK
31.05.2024Coca-Cola HoldJefferies & Company Inc.
07.05.2024Coca-Cola HaltenDZ BANK
25.04.2023Coca-Cola NeutralGoldman Sachs Group Inc.
24.04.2023Coca-Cola NeutralGoldman Sachs Group Inc.
DatumRatingAnalyst
16.02.2018Coca-Cola SellGoldman Sachs Group Inc.
10.01.2018Coca-Cola SellGoldman Sachs Group Inc.
17.11.2017Coca-Cola SellGoldman Sachs Group Inc.
16.11.2017Coca-Cola SellGoldman Sachs Group Inc.
26.10.2017Coca-Cola SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Coca-Cola Co. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen